Autoradiography characterization of novel alpha-synuclein radioligands [3H]Tg1-90B, [3H]M503-1619 and [3H]HY-2-15 in human post mortem brain
Objective: To characterize the in vitro binding properties of 3 radioligands for imaging α-syn aggregates in post mortem brain samples of synucleinopathies: [3H]TG-190B (Site 2),…Brain De-Ironization with Nasal Spray of Iron Chelator in Treatment of Multiple System Atrophy, a Case Trial
Objective: Iron removal seems to be a treatment approach in Multiple system atrophy (MSA) because pathological findings shows the accumulation of iron and α-synuclein protein…A Phase 2 Study of ATH434 a Novel Inhibitor of α-Synuclein Aggregation for the Treatment of Multiple System Atrophy
Objective: Describe baseline fluid and neuroimaging biomarker data of an early MSA study population Background: MSA is a rapidly progressive neurodegenerative disorder characterized by aggregated…Multifaceted Challenges in Multisystem Atrophy Management: Medication Sensitivity, Emotional Lability, and Increased Fall Risk
Objective: Multisystem atrophy (MSA) epitomizes a formidable quandary within neurological and geriatric disciplines, delineated by complex manifestations encompassing autonomic dysfunction, parkinsonism, and cerebellar ataxia. This…Pharmacokinetics And Safety Of YA-101, A Dual Inhibitors Of D-Amino Acid Oxidase (DAAO) And NLRP3 Inflammasome, In Healthy Subjects: A Double-Blind, Placebo-Controlled, Randomized, Single Dose and Multiple Dose Phase I Study
Objective: To evaluate the safety, tolerability, and pharmacokinetics (PK) profile of YA-101 in healthy volunteers with single dose and multiple dose Background: Multiple System Atrophy…Use of levodopa-carbidopa intestinal gel to treat a patient with multiple system atrophy (MSA)
Objective: To describe a case report on the use of Levodopa-carbidopa intestinal gel (LCIG) to treat non-motor symptoms in a patient with multiple system atrophy (MSA) Background: There is no…UMSARS versus laryngoscopy-based assessment of dysphagia
Objective: To compare the Unified Multiple System Atrophy Rating Scale (UMSARS) part I-item 2 with an ear/nose/throat (ENT) expert physician assessment. Background: Early and severe…Identifying a path to improve diagnostic delay and access to care for PSP, CBS, and MSA
Objective: To understand diagnosis and care experiences of patients and care partners living with progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy…Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy
Objective: IkT-148009 is a potent selective inhibitor of non-receptor Abelson Tyrosine Kinases (c-Abl kinases). Our recent analysis of post-mortem brain tissue from patients with Multiple…Baseline characteristics for patients with multiple system atrophy entering a randomized, controlled study of the anti-α-synuclein monoclonal antibody Lu AF82422
Objective: Report baseline characteristics for patients with multiple system atrophy (MSA) entering a study to assess the safety and efficacy of alpha-synuclein (α-syn) monoclonal antibody…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 8
- Next Page »